ZILASTOC

This brand name is authorized in South Africa.

Active ingredients

The drug ZILASTOC contains a combination of these active pharmaceutical ingredients (APIs):

`1`	Efavirenz UNII `JE6H2O27P8` - EFAVIRENZ
	Efavirenz is a NNRTI of HIV-1. Efavirenz is a non-competitive inhibitor of HIV-1 reverse transcriptase (RT) and does not significantly inhibit HIV-2 RT or cellular DNA polymerases (α, β, γ or δ).
	Read more about Efavirenz
`2`	Lamivudine UNII `2T8Q726O95` - LAMIVUDINE
	Lamivudine is a nucleoside analogue which has activity against human immunodeficiency virus (HIV) and hepatitis B virus (HBV). Its main mode of action is as a chain terminator of viral reverse transcription.
	Read more about Lamivudine
`3`	Zidovudine UNII `4B9XT59T7S` - ZIDOVUDINE
	Zidovudine is an antiviral agent which is highly active in vitro against retroviruses including the Human Immunodeficiency Virus (HIV).
	Read more about Zidovudine

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
ZA	Health Products Regulatory Authority	43/20.2.8/0775

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.